Literature DB >> 10331807

A system for the propagation of adenoviral vectors with genetically modified receptor specificities.

J T Douglas1, C R Miller, M Kim, I Dmitriev, G Mikheeva, V Krasnykh, D T Curiel.   

Abstract

The development of genetically modified adenovirus (Ad) vectors with specificity for a single cell type will require both the introduction of novel tropism determinants and the ablation of endogenous tropism. Consequently, it will not be possible to exploit the native cellular entry pathway in the propagation of these targeted Ad vectors. Based on the concept that Ad enters cells by a two-step process in which a primary receptor serves as a high affinity binding site for the Ad fiber knob, with subsequent internalization mediated by alpha v integrins, we designed two artificial primary receptors. The extracellular domain of one of these synthetic receptors was derived from a single-chain antibody (sFv) with specificity for Ad5 knob, while the second receptor consisted of an icosapeptide identified by biopanning a phage display library against Ad5 knob. Expression of either of these artificial virus-binding receptors in fiber receptor-negative cells possessing alpha v integrins conferred susceptibility to Ad infection. We then created a novel mechanism for cell binding by genetically modifying both the vector and the target cell. In this approach, six histidine (His) residues were incorporated at the C-terminal of the Ad fiber protein. The resultant Ad vector was able to infect nonpermissive cells displaying the cognate artificial receptor, containing an anti-His sFv. This strategy, comprising a genetically engineered Ad virion and a modified cell line, should be useful in the propagation of targeted Ad vectors that lack the ability to bind the native fiber receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331807     DOI: 10.1038/8647

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  42 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Dependence of adenovirus infectivity on length of the fiber shaft domain.

Authors:  D M Shayakhmetov; A Lieber
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Metabolic biotinylation of recombinant proteins in mammalian cells and in mice.

Authors:  M B Parrott; M A Barry
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Oncolytic measles virus retargeting by ligand display.

Authors:  Pavlos Msaouel; Ianko D Iankov; Cory Allen; Stephen J Russell; Evanthia Galanis
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

7.  Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation.

Authors:  A Pereboev; L Pereboeva; D T Curiel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.

Authors:  M H Verheije; T Würdinger; V W van Beusechem; C A M de Haan; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

9.  Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.

Authors:  Svetlana Komarova; Justin Roth; Ronald Alvarez; David T Curiel; Larisa Pereboeva
Journal:  J Ovarian Res       Date:  2010-05-25       Impact factor: 4.234

10.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.